# A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

> **NCT01121731** · PHASE1,PHASE2 · COMPLETED · sponsor: **Digna Biotech S.L.** · enrollment: 70 (actual)

## Conditions studied

- Chronic Hepatitis C Virus Infection
- Genotype 1
- Treatment-Experienced Patients
- Relapses

## Interventions

- **DRUG:** Interferon α-5
- **DRUG:** Interferon-α5 plus Interferon-α 2b
- **DRUG:** Interferon α-2b (INTRON® A)

## Key facts

- **NCT ID:** NCT01121731
- **Lead sponsor:** Digna Biotech S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-10
- **Final completion:** 2013-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121731, "A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01121731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*